ACUT:OTC-Accustem Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.2953

Change

0.00 (0.00)%

Market Cap

USD 4.14M

Volume

12.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

-2.24 (-1.77%)

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

+1.91 (+2.14%)

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

-1.09 (-1.64%)

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

+3.66 (+1.34%)

USD 18.12B
WXXWY WuXi Biologics (Cayman) Inc

+0.29 (+8.45%)

USD 7.17B
WXIBF WuXi Biologics

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing ACUT

DESE:LSE 1.22 % 0.00 %

N/A

N/A
WTEC:F 1.22 % 0.00 %

N/A

N/A
WTEC:XETRA 1.22 % 0.00 %

N/A

N/A
DESD:LSE 0.90 % 0.00 %

N/A

N/A
EQLT 0.45 % 0.75 %

N/A

N/A
SMD 0.42 % 0.10 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.80% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.80% 19% F 7% C-
Trailing 12 Months  
Capital Gain -77.96% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.96% 21% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.96% 54% F 53% F
Dividend Return 7.96% 54% F 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.81% 59% D- 45% F
Risk Adjusted Return 13.76% 62% D 48% F
Market Capitalization 4.14M 41% F 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.